hackint0sh/New-Dataset huggingface dataset:
Researchers will evaluate the possible benefits of FGG application in addition to non-surgical therapy by comparing the biochemical and clinical changes in areas with and without FGG application in the treatment of peri-implant mucositis. conditions: Peri-implant Mucositis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: Non-surgical treatment name: Free gingival graft measure: Inflammatory parameter levels in peri-implant crevicular fluid measure: Inflammatory parameter levels in peri-implant crevicular fluid measure: Inflammatory parameter levels in peri-implant crevicular fluid measure: Inflammatory parameter levels in peri-implant crevicular fluid measure: Plaque index (Silness & Löe, 1964) measure: Plaque index (Silness & Löe, 1964) measure: Plaque index (Silness & Löe, 1964) measure: Plaque index (Silness & Löe, 1964) measure: Gingival Index ( Löe & Silness,1963) measure: Gingival Index ( Löe & Silness,1963) measure: Gingival Index ( Löe & Silness,1963) measure: Gingival Index ( Löe & Silness,1963) measure: Bleeding on probing (Ainamo & Bay 1975) measure: Bleeding on probing (Ainamo & Bay 1975) measure: Bleeding on probing (Ainamo & Bay 1975) measure: Bleeding on probing (Ainamo & Bay 1975) measure: Keratinized mucosa width measure: Keratinized mucosa width measure: Keratinized mucosa width measure: Keratinized mucosa width measure: Probing depth measure: Probing depth measure: Probing depth measure: Probing depth sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Biruni University city: Istanbul country: Turkey name: Ayse E Selman role: CONTACT phone: +905366393184 email: aselman@biruni.edu.tr lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06304987 id: BFH-niCRT-05 briefTitle: Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-05 date: 2024-03-12 date: 2024-03-19 name: Beijing Friendship Hospital class: OTHER name: Peking Union Medical College Hospital name: Peking University Cancer Hospital & Institute name: Changhai Hospital briefSummary: This is a multicenter, prospective, randomized controlled study to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor in the treatment of patients with pMMR/MSS locally advanced middle and low rectal cancer. conditions: Locally Advanced Rectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Experimental: Neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor Control: Neoadjuvant chemoradiotherapy combined with PD-1 inhibitor primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor name: Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor measure: CR measure: AE rate measure: NAR score measure: OPR measure: ORR measure: immune-related adverse event rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Friendship Hospital, Capital Medical University city: Beijing state: Beijing zip: 100050 country: China lat: 39.9075 lon: 116.39723 facility: Beijing Friendship Hospital city: Beijing state: Beijing zip: 100050 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06304974 id: BL-B01D1-305 briefTitle: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma overallStatus: RECRUITING date: 2024-03-19 date: 2026-05 date: 2026-05 date: 2024-03-12 date: 2024-03-28 name: Sichuan Baili Pharmaceutical Co., Ltd. class: INDUSTRY name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. briefSummary: This study is a registered phase Ill, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody in combination with platinum-based chemotherapy. conditions: Esophageal Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 488 type: ESTIMATED name: BL-B01D1 name: Irinotecan name: paclitaxel name: docetaxel measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of Response (DOR) measure: Treatment Emergent Adverse Event (TEAE) measure: Cmax measure: T1/2 measure: Anti-drug antibody (ADA) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing state: Beijing country: China name: Lin Shen role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06304961 id: D9180C00011 briefTitle: A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers overallStatus: RECRUITING date: 2024-04-08 date: 2024-09-05 date: 2024-09-05 date: 2024-03-12 date: 2024-04-23 name: AstraZeneca class: INDUSTRY briefSummary: The study will assess the relative bioavailability between two dosage forms of tozorakimab (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles of both dosage forms. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 46 type: ESTIMATED name: Tozorakimab measure: Area under the concentration-time curve from time 0 to infinity (AUCinf) measure: Area under the concentration-curve from time 0 to the last quantifiable concentration (AUClast) measure: Maximum observed drug concentration (Cmax) measure: Time to reach peak or maximum observed concentration following tozorakimab administration (tmax) measure: Terminal elimination half-life (t1/2) measure: Terminal rate constant (λz) measure: Apparent total body clearance (CL/F) measure: Apparent volume of distribution based on the terminal phase (Vz/F) measure: Number of participants with adverse events (AEs) measure: Number of participants with presence of Anti-Drug Anitbodies (ADAs) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Research Site status: RECRUITING city: Berlin zip: 14050 country: Germany lat: 52.52437 lon: 13.41053 hasResults: False
nctId: NCT06304948 id: Vitamin D and migraine briefTitle: The Link Between Human Cytomegalovirus Gene Expression and Glutamate Level in Migraine;Relation to Vitamin D Deficiency overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-01 date: 2025-02 date: 2024-03-12 date: 2024-03-26 name: Assiut University class: OTHER briefSummary: 1. To correlate serum 25(OH)-vitamin D level with duration, frequency, and severity of migraine headache attacks
3. To correlate the serum level of glutamate with gene expression of in migraine conditions: Migraine studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 72 type: ESTIMATED measure: The Link between human cytomegalovirus gene expression and glutamate levels in Migraine :relationship to the Vit D Deficiency sex: ALL minimumAge: 15 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06304935 id: IPRF effect post tonsillectomy briefTitle: Injectable Platelet Rich Fibrin Post Tonsillectomy overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-01 date: 2025-07-01 date: 2024-03-12 date: 2024-04-19 name: Assiut University class: OTHER briefSummary: To evaluate the effect of injectable Prf on healing, hemostasis and pain post tonsillectomy conditions: IPRF Post Tonsillectomy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: Use of injectable platelet rich fibrin after tonsillectomy by injection of IPRF in one tonsillar bed and use of other side as control measure: IPRF effect on healing measure: IPRF effect on post tonsillectomy pain and bleeding sex: ALL minimumAge: 5 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304922 id: BRCA 1/2 in cancer ovary briefTitle: BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2026-04-01 date: 2024-03-12 date: 2024-03-12 name: Assiut University class: OTHER briefSummary: The main objective of this prospective study is to assess the clinical outcomes of platinum based chemotherapy cases either cisplatin or carboplatin according to BRCA status in neoadjuvant and recurrent ovarian cancer. conditions: Ovarian Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 45 type: ESTIMATED name: Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer measure: Objective response rate. measure: Progression free survival measure: Overall survival and toxicity sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304909 id: 2080278 briefTitle: Effect of Intravenous Dexmedetomidine Versus Dexamethasone for Management of Repound Pain After Supraclavicular Brachial Plexus Block overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-03 date: 2025-03 date: 2024-03-12 date: 2024-04-23 name: Assiut University class: OTHER briefSummary: Effect of intravenous dexmedetomidine versus dexamethasone for management of repound pain after supraclavicular brachial plexus block. conditions: Trauma Injury studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 111 type: ESTIMATED name: Dexmedetomidine injection measure: The incidence of rebound pain. sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06304896 id: #18240343 briefTitle: Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy acronym: BASiC-CIC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-12-01 date: 2024-03-12 date: 2024-03-12 name: Arab Contractors Medical Centre class: OTHER briefSummary: BASiC-CIC Trial is a multicenter, double-blinded, randomized, placebo-controlled clinical trial to investigate whether repurposing colchicine or a combination of beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins will be effective as a prophylactic treatment for the prevention of chemotherapy-induced cardiomyopathy, reduction of major adverse cardiovascular events, and all-cause mortality. conditions: Chemotherapy Induced Systolic Dysfunction studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 150 type: ESTIMATED name: Carvedilol name: Ramipril name: Rosuvastatin name: Colchicine name: Placebo measure: Chemotherapy-induced cardiomyopathy measure: Chemotherapy-induced cardiomyopathy measure: Major Adverse Cardiovascular Events measure: All-Cause Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Arab Contractors Medical Centre city: Cairo country: Egypt name: Eslam Abbas, MBChB, MSc role: CONTACT phone: 01023054574 phoneExt: +2 email: islam.omr@med.au.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06304870 id: SYB-reflux briefTitle: Impact of Blocking the Glossopharyngeal Nerve on Gastroesophageal Reflux Disease overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-03-12 date: 2024-03-15 name: Muhammad class: OTHER briefSummary: The goal of this clinical trial is to explore Clinical Effect of Glossopharyngeal Nerve Block on Pharyngeal Dysphagia Induced by Gastroesophageal Reflux Disease. The main question it aims to answer is:
• Can Glossopharyngeal Nerve Block improve dysphagia caused by gastroesophageal reflux symptoms on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Glossopharyngeal Nerve Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Rosenbek penetration-aspiration scale, Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, to see if the Glossopharyngeal Nerve Block can help improve the symptom. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Rehabilitation therapy name: Lidocaine name: Injection measure: Rosenbek penetration-aspiration scale measure: Gastroesophageal Reflux Disease Questionnaire measure: Pressure pain threshold sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304857 id: 2022/ABM/01/00039 id: 2023-506631-15-00 type: OTHER domain: EUCT briefTitle: CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - PROTECTAA TRIAL acronym: PROTECTAA overallStatus: RECRUITING date: 2024-04-15 date: 2026-12-31 date: 2027-12-31 date: 2024-03-12 date: 2024-04-25 name: 4th Military Clinical Hospital with Polyclinic, Poland class: OTHER briefSummary: The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment. conditions: Breast Cancer conditions: Heart Failure studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 188 type: ESTIMATED name: Dapagliflozin name: Placebo measure: Primary efficacy composite endpoint (cancer therapeutics related cardiac dysfunction) at 12 months. measure: Secondary efficacy composite endpoint (cancer therapeutics related cardiac dysfunction) at 6 months. measure: Change in left ventricular ejection fraction at 6 and 12 months. measure: Change in left ventricular diastolic function at 6 and 12 months. measure: Change in Troponin I after 6 and 12 months. measure: Change in NTproBNP levels at 6 and 12 months. measure: Quality of life at 6 and 12 months assessed using the five-dimensional EQ-5D questionnaire. measure: Occurrence of death from any cause. measure: Composite endpoint of cardiovascular events. measure: Occurrence of death from any cardiovascular reasons. measure: Occurrence of non-fatal myocardial infarction. measure: Occurrence of non-fatal stroke. measure: Occurrence of hypoglycaemia. measure: Occurrence of ionic disorders. measure: Occurrence of renal failure. measure: Occurrence of hypersensitivity to investigated drug. measure: Occurrence of allergic reactions. measure: Occurrence of infection. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: 4th Military Clinical Hospital with Polyclinic status: RECRUITING city: Wrocław state: Dolnośląskie zip: 50-981 country: Poland name: Bartosz Krakowiak, PhD, MD role: CONTACT phone: +48 261 660 234 email: bkrakowiak@4wsk.pl lat: 51.1 lon: 17.03333 facility: Lower Silesian Centre for Oncology, Lung Diseases and Hematology status: RECRUITING city: Wrocław state: Dolnośląskie zip: 53-413 country: Poland name: Rafał Matkowski, PhD, MD role: CONTACT lat: 51.1 lon: 17.03333 facility: Military Medical Institute status: NOT_YET_RECRUITING city: Warsaw state: Mazowieckie zip: 04-141 country: Poland name: Paweł Krzesiński, PhD, MD role: CONTACT lat: 52.22977 lon: 21.01178 hasResults: False
nctId: NCT06304844 id: Soh-Med-24-02-06MD briefTitle: Risk of CKD in Diabetic Patients With MAFLD overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2024-10-01 date: 2025-02-01 date: 2024-03-12 date: 2024-03-18 name: Sohag University class: OTHER briefSummary: This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes. By evaluating hepatic measurements and metabolic markers, the study aims to identify key risk factors for CKD in this population, contributing valuable insights to inform targeted interventions. conditions: Type 2 Diabetes studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: transient elastography (Fibroscan) measure: Determine the number of participant with eGFR<60 ml/min/1.73 m2 or albuminuria (urinary albumin-to-creatinine ratio (ACR) ⩾3 mg/mmol) in patients with type 2 DM and MAFLD sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304818 id: SCTB14-X101 briefTitle: Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2027-12-30 date: 2028-12-30 date: 2024-03-12 date: 2024-03-15 name: Sinocelltech Ltd. class: INDUSTRY briefSummary: This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB14 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial. conditions: Advanced Malignant Solid Tumours studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 515 type: ESTIMATED name: SCTB14 measure: Dose-Limiting toxicity(DLT) measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Progression-free survival (PFS) measure: Overall survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304805 id: TGRX-326-1002 briefTitle: TGRX-326 Phase I/II Pharmacokinetic Study overallStatus: COMPLETED date: 2023-12-13 date: 2024-01-12 date: 2024-01-19 date: 2024-03-12 date: 2024-04-10 name: Shenzhen TargetRx, Inc. class: INDUSTRY name: First Affiliated Hospital Bengbu Medical College briefSummary: A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-326 and the effect of different drug specifications on human bioavailability for TGRX-326, a drug indicated for non-small cell lung cancer treatment conditions: Non Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE maskingDescription: This is a PK assessment study, hence only bio-sample analysis personnel were masked for the type of treatment received for each sample to avoid bias in analysis. Other study personnel, including participants, investigators and staffs were not masked for treatment types. whoMasked: OUTCOMES_ASSESSOR count: 24 type: ACTUAL name: cycle 1: treatment drug name: cycle 1: reference drug name: cycle 1: fasted name: cycle 1: food name: cycle 2: treatment drug name: cycle 2: reference drug name: cycle 2: fasted name: cycle 2: food name: cycle 3: treatment drug name: cycle 3: reference drug name: cycle 3: fasted name: cycle 3: food measure: Plasma Cmax measure: Plasma AUC(0-t) measure: Plasma AUC(0-inf) measure: Plasma Tmax measure: terminal elimination rate constant (lambda-z) measure: Elimination half-life (T1/2-Z) measure: AUC(%Extrap) measure: Plasma volume of distribution (Vz/F) measure: Plasma clearance (CL/F) measure: Adverse events/serious adverse events sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: First Affiliated Hospital Bengbu Medical College city: Bengbu state: Anhui zip: 233004 country: China lat: 32.94083 lon: 117.36083 hasResults: False
nctId: NCT06304792 id: H-22030591 briefTitle: Immediate Versus Postponed Single Blastocyst Transfer in Programmed or Stimulated Cycle Frozen Embryo Transfer overallStatus: RECRUITING date: 2024-02-01 date: 2028-08-01 date: 2028-08-01 date: 2024-03-12 date: 2024-03-12 name: Rigshospitalet, Denmark class: OTHER briefSummary: The aim of this randomized controlled trial is to examine whether single blastocyst transfer in the first cycle after oocyte retrieval (immediate) is non-inferior to single blastocyst transfer in a subsequent cycle (postponed) in stimulated or programmed cycle frozen embryo transfer (FET). The primary outcome is live birth rate. conditions: Infertility conditions: IVF studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 464 type: ESTIMATED name: Immediate FET in a stimulated or programmed cycle measure: Live birth rate measure: Live birth rate per blastocyst transfer measure: Ongoing pregnancy rate measure: Miscarriage rate measure: Cancelled cycle rate and reason for cancelled cycles measure: Endocrinology of the luteal phase measure: Number of ovarian follicular structures >10 mm measure: Time-to-pregnancy measure: Time-to-live-birth measure: Pregnancy related complications measure: Neonatal outcomes (weight in kilograms) measure: Neonatal outcomes (length in cm) measure: Neonatal outcomes (apgar score at 1, 5 and 10 minutes postpartum) measure: Quality of life based on the Copenhagen Multicenter Psychosocial Infertility (COMPI) stress scale questionnaires sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Fertility Departmen, Rigshospitalet status: RECRUITING city: Copenhagen zip: 2100 country: Denmark name: Anja B. Pinborg, Prof., DMSC role: CONTACT phone: 0045 35 45 64 30 email: anja.bisgaard.pinborg@regionh.dk name: Clara Colombo, MD role: CONTACT email: clara.colombo@regionh.dk lat: 55.67594 lon: 12.56553 hasResults: False